October 6th, 2025 | 07:05 CEST
Novo Nordisk, FuelCell Energy and Almonty Industries stage strong rebound
While many analysts are concerned about high valuations on the global stock markets, with the Warren Buffett indicator at a historic high, even exceeding its value before the dot-com bubble, the markets continue to rise from one high to the next. In fact, several companies staged a strong rebound last week, which is likely to pave the way for further gains by generating fresh buy signals.
time to read: 4 minutes
|
Author:
Stefan Feulner
ISIN:
NOVO NORDISK A/S | DK0062498333 , FUELCELL ENERGY DL-_0001 | US35952H6018 , ALMONTY INDUSTRIES INC. | CA0203987072
Table of contents:
"[...] While tungsten has always played an important role in the chip industry, it is now being added to batteries for e-cars. [...]" Lewis Black, CEO, Almonty Industries
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Almonty Industries – New all-time highs beckon
For months, business has been running like clockwork for tungsten producer Almonty Industries. In addition to placing a capital increase and raising USD 90 million, followed by a Nasdaq listing, the Canadian company is also right on schedule with the start of production at the Sangdong mine in South Korea. At full capacity, the mine is expected to cover over 80% of Western non-Chinese production. It is therefore considered one of the Western world's greatest hopes for the procurement of critical raw materials.
Nevertheless, immediately after the successful Nasdaq listing, Almonty shares experienced a "sell on good news" effect. After climbing to a new all-time high of CAD 8.66, the share price corrected by almost 50% to an interim low of CAD 4.36 at the end of July, which turned out to be a unique opportunity for investors to buy more shares. In the meantime, the share price has rebounded strongly and generated a new all-time high of CAD 8.76.
In addition to the fact that production in South Korea is expected to start before the end of this calendar year, the stock is likely to continue to rise. Furthermore, Almonty Industries, led by CEO Lewis Black, has another ace up its sleeve that has barely contributed to the valuation so far. In addition to tungsten, the Sangdong property also contains molybdenum, another strategic metal used not only in the defense industry but also in steel refining and alternative energy. A drilling program has now been launched to analyze the previously identified structures more precisely and to define potential reserves.
CEO Lewis Black will present Almonty Industries at the upcoming 16th International Investment Forum (IIF). Registration for the virtual event is free of charge.
Novo Nordisk – Optimism prevails
The Danish flagship company, which specializes primarily in chronic diseases and metabolic disorders, has shown the first signs of bottoming out in recent weeks. After a sharp decline since June of last year and a loss of around 70% to a low of USD 45.05, the pharmaceutical company is gradually moving northward. The share price is currently USD 59.63, just shy of the horizontal resistance level at USD 60.20. A sustained break above this level would give the share potential to rise to USD 70.
Analysts at HSBC see further potential for Novo shares. The major British bank has upgraded the Danish pharmaceutical giant's stock from "Hold" to "Buy". Analyst Rajesh Kumar cites the strong pipeline, focus on reimbursable drugs, and direct sales as a clear recipe for success. Novo has no reason to shy away from comparison with its US competitor Eli Lilly in particular.
"Given the latest clinical data on Orforglipron and oral semaglutide, it is difficult to argue that Novo is at a disadvantage," said Kumar. The outlook also promises potential. According to HSBC, new study data on CagriSema and oral semaglutide could offer an attractive risk-reward ratio.
The upgrade came in an already bullish sector. Healthcare stocks had already gained ground across Europe the day before. The reason: a deal between US pharmaceutical giant Pfizer and the US government to lower drug prices in the Medicaid program provided some relief, with tariff reductions in return.
FuelCell Energy – Riding the wave of Plug Power
The recent upward movements in the hydrogen fuel cell sector are reminiscent of 2020, when the industry reached one high after another, despite its sometimes exaggerated valuations. FuelCell shares shot up by around 168% to USD 10.21 in less than four weeks. However, when viewed in relation to the previous loss, this is only a drop in the ocean. The stock's all-time high was reached in February 2021 at a staggering USD 883.19. Since then, FuelCell shares have crashed by over 98%.
The trigger for the recent upward movement was provided by peer group company Plug Power, which gave the entire industry a boost following a milestone announcement. The US hydrogen specialist has delivered its first 10-megawatt electrolyser module to Portuguese energy group Galp, marking the start of its largest project to date. The refinery in the coastal town of Sines is home to nothing less than the largest PEM electrolyser project in Europe. A total of ten of these modules are to be installed by 2026, delivering a whopping 100 megawatts of power.
Up to 15,000 tons of green hydrogen per year are to be produced, replacing 20% of the gray hydrogen used to date. This is a breakthrough for the environment, as it could save around 110,000 tons of CO₂ annually, according to the Company. It is an important step toward decarbonizing the European refinery sector.
Plug CEO Andy Marsh is convinced: "Our partnership with Galp proves that green hydrogen already works on an industrial scale today."
Despite exaggerated valuations, global stock markets continue to rise from one high to the next. Tungsten producer Almonty Industries has also celebrated a rebound to a new all-time high. FuelCell Energy benefited from positive industry news, while Novo Nordisk is viewed positively by analysts.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
